Your institution may have access to this item. Find your institution then sign in to continue.
Title
BioCryst Wins US Contract to Continue Ebola Drug Development.
Abstract
The article informs that BioCryst Pharmaceutical Inc. has received contract from the U.S. government to continue development of its treatment for Ebola diseases and also reveals that U.S. National Institutes of Health (NIH) is funding the development of the intramuscular formulation of the drug.